Embodiments are disclosed of a method of controlling timing and/or dosage of a transdermal drug patch. For example, a control device operative to move the patch to one or more of a plurality of operational relationships with a skin of a patient, including being fully engaged with the skin, partially engaged with the skin, and disengaged with the skin. The device may include a roller that peels a patch on and off the skin. Optionally a convention patch is used. In some embodiments a patch and/or an adaptor has a mobile zone and an immobile zone. In some embodiments, an active surface of the patch fully contacts the skin in an engaged state. For example the patch may be attached to the device on a passive portion thereof.

A percutaneous absorption agent delivery device with: a solvent-impermeable cover film that has a first layer and a second layer, which are integrally continuous via a first fold and are superimposed, a non-seal region and a seal region are formed between the first layer and the second layer, the non-seal region disposed along the first fold, the seal region to surround the outer peripheral section of the non-seal region except for the section along the first fold, and an endless cut portion forming the non-seal region formed in the cover film; a percutaneous absorption agent carrying member is disposed in the non-seal region between the first layer and the second layer, and fixed to the cover film on the inner side of the cut portion; and an adhesive sheet that is detachably affixed to the outer surface of the cover film.

The invention relates to a method for manufacturing a transdermal patch from a drug-containing web that minimizes waste. The web is a layered composite that includes at least a backing layer and a drug-in-adhesive layer and a first strippable release liner. The web is kiss-cut along intersecting cut lines at least down to the depth of the liner, generally defining the extent of individual transdermal patches. The intersections of the cut lines define small zones that are punched out of the web in a generally star shape. The portions of the web above the liner are peeled away from the liner and transferred to a faster moving second liner so that the patches are now further spaced apart from one another. This second liner is then cut to provide transdermal patches that are mounted to release liners that are substantially broader in extent than the patches themselves.

The invention relates to a method for manufacturing a transdermal patch from a drug-containing web that minimizes waste. The web is a layered composite that includes at least a backing layer and a drug-in-adhesive layer and a first strippable release liner. The web is kiss-cut along intersecting cut lines at least down to the depth of the liner, generally defining the extent of individual transdermal patches. The intersections of the cut lines define small zones that are punched out of the web in a generally star shape. The portions of the web above the liner are peeled away from the liner and transferred to a faster moving second liner so that the patches are now further spaced apart from one another. This second liner is then cut to provide transdermal patches that are mounted to release liners that are substantially broader in extent than the patches themselves.

A modular transdermal drug delivery system is provided, the system including: an upper module in which an outer backing layer is laminated to a pressure-sensitive adhesive layer that is covered by a removable release liner prior to assembly; and a lower module with a porous drug reservoir layer laminated to a skin-contact adhesive that affixes the system to the skin during drug delivery, where the skin-contact adhesive is, in one embodiment, an adhesive layer that is substantially co-extensive with the porous drug reservoir layer and, prior to use, protected with a second removable release liner. Methods of manufacture and use are also provided, as is an assembled transdermal drug delivery system fabricated by affixing the pressure-sensitive adhesive layer of the upper module to the porous drug reservoir layer of the lower module.

Transdermal therapeutic systems are described which have at least one electronic component, as well as methods for producing this type of transdermal therapeutic systems.

Described is a transdermal device comprising a backing layer; a single layer adhesive matrix comprising buprenorphine or a salt thereof, a pressure sensitive adhesive including a silicone-type adhesive blended with an acrylate-type adhesive, a solubilizer, a permeation enhancer, and a crystallization inhibitor; and a release layer. Also described is a method of relieving pain and a method of preparing a transdermal delivery system.

Transdermal therapeutic systems are described which have at least one electronic component, as well as methods for producing this type of transdermal therapeutic systems.

Provided is a mold for manufacturing a skin attachable thin film, the mold including: a cast part having a U shape to accommodate a mixed solution in an inner space, and including a lower surface part and a side part, and an inner space accommodating the mixed solution; and at least one protruding pillar protruding from at least a partial region of the lower surface part.

The present invention relates to transdermal therapeutic systems (TTS) for the transdermal administration of solifenacin.